The patent for semaglutide, the main component in the weight-loss and diabetes medications Ozempic and Wegovy, is set to expire in Brazil, marking a significant shift in the pharmaceutical landscape controlled so far by Novo Nordisk. With the expiration, other pharmaceutical companies will be able to produce and sell versions of these popular drugs, provided they receive authorization from Anvisa, Brazil's health regulatory agency. This development has the potential to democratize access to these treatments, which have been noted for their effectiveness in managing obesity and diabetes.

Expectations are high that the entry of generic equivalents could lead to a decrease in drug prices by as much as 35%, a prospect that has been highlighted by EMS, one of the companies gearing up to produce a local version of semaglutide. Patients may be eager for more affordable options, but experts caution that the impact may not be immediate, as the approval process for new medications can take time before they hit pharmacy shelves. Currently, Anvisa is evaluating several applications for semaglutide, with two primary competitors to Novo Nordisk, EMS and Ávita Care, awaiting the green light.

As the situation develops, there remains a level of uncertainty regarding when these similar medications will be available to patients and how they will actually affect market dynamics. Neuton Ornelas, president of the Brazilian Society of Endocrinology, points out that, while this change marks a critical moment for pharmaceutical access, the immediate benefits for patients may be limited until all logistical and regulatory hurdles are successfully cleared and the new treatments enter the market.